PD-1/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression

• Published in: Nature Communications
• Main Authors: Lin-Zhou Zhang, Jie-Gang Yang, Gai-Li Chen, Qi-Hui Xie, Qiu-Yun Fu, Hou-Fu Xia, Yi-Cun Li, Jue Huang, Ye Li, Min Wu, Hai-Ming Liu, Fu-Bing Wang, Ke-Zhen Yi, Huan-Gang Jiang, Fu-Xiang Zhou, Wei Wang, Zi-Li Yu, Wei Zhang, Ya-Hua Zhong, Zhuan Bian, Hong-Yu Yang, Bing Liu, Gang Chen
• Format: Article
• Language: English
• Published: Nature Portfolio 2024-05-01
• Online Access: https://doi.org/10.1038/s41467-024-48200-9

Abstract Only a minority of cancer patients benefit from immune checkpoint blockade therapy. Sophisticated cross-talk among different immune checkpoint pathways as well as interaction pattern of immune checkpoint molecules carried on circulating small extracellular vesicles (sEV) might contribute to the low response rate. Here we demonstrate that PD-1 and CD80 carried on immunocyte-derived sEVs (I-sEV) induce an adaptive redistribution of PD-L1 in tumour cells. The resulting decreased cell membrane PD-L1 expression and increased sEV PD-L1 secretion into the circulation contribute to systemic immunosuppression. PD-1/CD80+ I-sEVs also induce downregulation of adhesion- and antigen presentation-related molecules on tumour cells and impaired immune cell infiltration, thereby converting tumours to an immunologically cold phenotype. Moreover, synchronous analysis of multiple checkpoint molecules, including PD-1, CD80 and PD-L1, on circulating sEVs distinguishes clinical responders from those patients who poorly respond to anti-PD-1 treatment. Altogether, our study shows that sEVs carry multiple inhibitory immune checkpoints proteins, which form a potentially targetable adaptive loop to suppress antitumour immunity.